Skip to main content Skip to search Skip to main navigation

EMA: Public Consultation of Annexes to ICH Q3C and VICH GL18 on Residual Solvents

The European Medicines Agency (EMA) has published revised annexes to the ICH Q3C guideline (“Impurities: Guideline for Residual Solvents”) and the corresponding veterinary guideline VICH GL18 for public consultation. The commenting period is open until the end of June 2026.

The revision aims primarily to align the annexes with the latest version of the ICH Q3C guideline (up to Revision R9) and to further harmonise requirements between human and veterinary medicinal products. In addition, the update addresses practical challenges and ambiguities observed in regulatory assessment and inspections.

The changes concern Annex I only, while Annex II remains unchanged. A key new feature is the introduction of decision trees, intended to provide structured guidance on the control of residual solvents. These are designed to support consistent decision-making regarding when testing is required, when specifications need to be established, and how appropriate control strategies can be justified.

Furthermore, the revised annex includes more explicit expectations regarding the management of manufacturing changes, such as changes in starting materials, suppliers, or process parameters. In such cases, a more systematic assessment of the impact on residual solvents is required, including, where appropriate, revalidation activities.


Source:

EMA: Annexes to: EMA/CHMP/ICH/82260/2006 - ICH Q3C Guideline on impurities: guideline for residual solvents and EMA/CVMP/VICH/502/1999 - VICH GL18 Impurities: residual solvents in new veterinary medicinal products, active substances and excipients

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

EDQM: Updated Guideline on CEP Revisions and Renewals

EDQM: Updated Guideline on CEP Revisions and Renewals

The European Directorate for the Quality of Medicines & HealthCare has published a revised version of its guideline on the revision and renewal of Certificates of Suitability (CEPs) (PA/PH/CEP (04) 02), aligning it with recent EU legislation on variation procedures.
Read more
EMA: Public Consultation of Annexes to ICH Q3C and VICH GL18 on Residual Solvents

EMA: Public Consultation of Annexes to ICH Q3C and VICH GL18 on Residual Solvents

The European Medicines Agency (EMA) has published revised annexes to the ICH Q3C guideline (“Impurities: Guideline for Residual Solvents”) and the corresponding veterinary guideline VICH GL18 for public consultation. The commenting period is open until the end of June 2026.
Read more
FDA: New Draft Guidance on Impurity Specifications for Antibiotics

FDA: New Draft Guidance on Impurity Specifications for Antibiotics

The US FDA has issued a new draft guidance (April 2026) on Impurity Specifications for Antibiotics.
Read more
EDQM: Guidance on Traceability of Medicines in Hospitals

EDQM: Guidance on Traceability of Medicines in Hospitals

The EDQM has published new guidance on the traceability of medicines in hospital settings. The aim is to improve traceability up to the point of administration and strengthen patient safety.
Read more
Which Measures are Crucial for Implementation and Monitoring of Data Integrity?

Which Measures are Crucial for Implementation and Monitoring of Data Integrity?

Here's the answer:
Read more
Contamination Control Strategy (CCS) – Not Just an Extended Site Master File

Contamination Control Strategy (CCS) – Not Just an Extended Site Master File

At the GMP-PharmaCongress in Wiesbaden, GMP inspector Frank Sielaff (Regional Authority in Darmstadt, Germany) shared practical insights from recent inspections, high-lighting deficiencies in CCS implementation.

Read more
Previous
Next